Table 3.
Genes upregulated specifically in Sox9-EGFP High cells
| Symbol | Gene Name | Fold Change | ID |
|---|---|---|---|
| NTS | neurotensin | 101.80 | 67405 |
| TAC1 | tachykinin, precursor 1 | 60.44 | 21333 |
| CHGB | chromogranin B (secretogranin 1) | 56.17 | 12653 |
| CCK | cholecystokinin | 24.96 | 12424 |
| GCG | glucagon | 23.36 | 14526 |
| CHGA | chromogranin A (parathyroid secretory protein 1) | 22.31 | 12652 |
| SCT | secretin | 17.95 | 20287 |
| GIP | gastric inhibitory polypeptide | 16.23 | 14607 |
| GHRL | ghrelin/obestatin prepropeptide | 3.46 | 58991 |
| SOX9 | SRY-box containing gene 9 | 12.03 | 20682 |
| BMI1 | Bmi1 polycomb ring finger oncogene | 2.65 | 12151 |
| HOPX | HOP homeobox | 4.15 | 74318 |
Endogenous Sox9 was specifically highly enriched in the cells ecpressing high levels of Sox9-EGFP (Sox9-EGFP High cells; bold font). Enteroendcrine cell (EEC) markers, as well as BMI1 and HOPX (bold font), 2 markers of slowly cycling or quiescent ISCs (54, 61), were also specifically enriched in Sox9-EGFP High cells. Fold change is expressed vs. gene expression in Sox9-EGFP Negative cells.